EZAG Holding | Press Releases

Eckert & Ziegler Achieves Further Earnings Growth and Double-Digit Sales...

11/13/2025

Eckert & Ziegler Gains Approval for GalliaPharm® in Japan

09/19/2025

Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation...

09/09/2025

Eckert & Ziegler: Further Increase in Earnings in the First...

08/08/2025

Eckert & Ziegler: Implementation of the Share Split by Issuing...

08/05/2025

Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation...

07/29/2025

Eckert & Ziegler: Capital Increase Entered in the Commercial Register....

07/28/2025

Eckert & Ziegler: Outstanding Training Quality Once Again Awarded

07/15/2025

Annual General Meeting of Eckert & Ziegler SE Approves Dividend...

06/18/2025

Eckert & Ziegler: Illuccix® PSMA-PET Imaging Agent Receives Approval in...

06/05/2025

Eckert & Ziegler Organizes Third Boston Radionuclide Theranostics Forum

05/30/2025

Eckert & Ziegler Wins “Best Managed Companies Award” for the...

05/23/2025

Eckert & Ziegler Starts with Earnings Growth in Q1 2025...

05/13/2025

Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher...

04/24/2025

Eckert & Ziegler Proposes Dividend of € 0.50 for...

04/11/2025

Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig

04/10/2025

Eckert & Ziegler: Record year 2024 with new all-time highs

03/27/2025

Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for...

03/25/2025

Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global...

03/20/2025

Eckert & Ziegler Enters Strategic Partnership with Bicycle Therapeutics for...

02/27/2025

Eckert & Ziegler Ensures Business Continuity After Cyber-Attack

02/25/2025

Eckert & Ziegler Affected by Cyber Attack

02/13/2025 9:21 am CET (Ad hoc-Message)

Eckert & Ziegler SE: IT Incident Affects Eckert & Ziegler...

02/03/2025

Eckert & Ziegler Announces Preliminary Figures for 2024: Significant Increase...

01/27/2025 6:55 pm CET (Ad hoc-Message)

Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese...

01/14/2025 5:03 pm CET (Ad hoc-Message)

Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply...

01/13/2025

Eckert & Ziegler Submits GalliaPharm® for Approval by Japan’s Health...

12/13/2024

Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement...

12/05/2024

Eckert & Ziegler: Changes in the Executive Board and Supervisory...

12/03/2024

Eckert & Ziegler Begins Production of Actinium-225, Paving the Way...

12/02/2024

Eckert & Ziegler Achieves European Approval for Theralugand® - Lutetium-177...

11/27/2024

Eckert & Ziegler raises its forecast for the current financial...

11/22/2024 3:27 pm CET (Ad hoc-Message)

Eckert & Ziegler Continues on Growth Path with Strong 9-Month...

11/14/2024

Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration...

11/13/2024 8:54 am CET (Ad hoc-Message)

Eckert & Ziegler Again Increases Sales and Earnings in the...

10/15/2024 4:33 pm CEST (Ad hoc-Message)

Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply...

10/08/2024

Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the...

10/02/2024

Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering...

08/20/2024

Eckert & Ziegler becomes European contract manufacturer for Telix's innovative...

08/13/2024

Eckert & Ziegler Continues Sales and Earnings Growth in the...

08/09/2024

Eckert & Ziegler extends GalliaPharm® availability to the entire European...

08/05/2024

Eckert & Ziegler Again Increases Sales and Earnings Compared to...

07/16/2024 2:26 pm CEST (Ad hoc-Message)

Annual General Meeting of Eckert & Ziegler SE Approves Split-Off...

06/26/2024

Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to...

06/25/2024

Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility

06/19/2024

Eckert & Ziegler Hosts Second Radionuclide Theranostics Forum in Boston,...

05/31/2024

Eckert & Ziegler receives “Best Managed Companies Award”

05/24/2024

Eckert & Ziegler with significant increase in sales (+17%) and...

05/14/2024

Eckert & Ziegler: Q1 with Significant Increase in Sales and...

04/22/2024 2:49 pm CEST (Ad hoc-Message)

Eckert & Ziegler Continues on Growth Path after Successful Financial...

03/22/2024

Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving...

03/21/2024

Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings...

03/19/2024 7:46 pm CET (Ad hoc-Message)

Eckert & Ziegler Completes Change of Legal Form to SE

03/19/2024

Eckert & Ziegler Extends Ga-68 Activities in Japan

02/28/2024

Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes...

01/31/2024

Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement...

01/23/2024

Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership...

01/08/2024

First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study...

11/22/2023

Eckert & Ziegler: Personnel Changes in the Management. Changes in...

11/21/2023

Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma...

11/14/2023 12:04 pm CET (Ad hoc-Message)

Eckert & Ziegler with Significant Sales Growth in the First...

11/14/2023

Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for...

10/23/2023

Eckert & Ziegler and Supervisory Board Decide on Investment Priorities...

10/20/2023

Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off...

10/20/2023 3:18 pm CEST (Ad hoc-Message)

Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous...

10/17/2023 4:57 pm CEST (Ad hoc-Message)

Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply...

10/10/2023

Eckert & Ziegler Receives Award for Professional Training

09/28/2023

Eckert & Ziegler Signs Strategically Important Agreement for the Supply...

09/25/2023 11:17 pm CEST (Ad hoc-Message)

Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals...

09/13/2023

Eckert & Ziegler Continues Positive Sales Development in the First...

08/10/2023

Eckert & Ziegler again achieves sales growth compared to the...

07/21/2023 3:21 pm CEST (Ad hoc-Message)

Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to...

06/08/2023

ckert & Ziegler: Annual General Meeting Approves Dividend of EUR...

06/07/2023

Eckert & Ziegler to Host First Radionuclide Theranostics Forum in...

05/30/2023

Reorganization in the Executive Board of Eckert & Ziegler

05/15/2023

Eckert & Ziegler with Strong Sales Growth in the First...

05/11/2023

Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins...

05/08/2023

Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit...

04/25/2023 5:59 pm CEST (Ad hoc-Message)

Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177

04/20/2023

Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site

04/12/2023

Eckert & Ziegler to Supply POINT Biopharma with Actinium-225

04/04/2023

Eckert & Ziegler: Successful fiscal year 2022

03/30/2023

Eckert & Ziegler Plans Change of Legal Form to European...

03/24/2023

Eckert & Ziegler with Unchanged Dividend Proposal

03/23/2023

Eckert & Ziegler Submits Drug Master File for Lu-177 n.c.a.

03/03/2023

Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting

02/01/2023

Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year...

01/17/2023 12:47 pm CET (Ad hoc-Message)

Change in the Supervisory Board of Eckert & Ziegler AG

12/20/2022

Changes in the Management Board of Eckert & Ziegler

12/19/2022 1:29 pm CET (Ad hoc-Message)

Eckert & Ziegler Receives Green Light for Phase III Study...

11/25/2022 3:36 pm CET (Ad hoc-Message)

Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth

11/08/2022

First CNS Lymphoma Patient Imaged with PentixaFor in Phase 2...

10/27/2022

Eckert & Ziegler and Alpha-9 Sign Actinium-225 (Ac-225) Reservation Agreement

10/13/2022

Eckert & Ziegler to Build Production Line for NorthStar Medical...

10/11/2022

Eckert & Ziegler with Successful First Half of 2022

08/11/2022

Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from...

08/04/2022

Eckert & Ziegler: Strong Growth in Revenues and Earnings in...

07/27/2022

Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical...

07/21/2022

Eckert & Ziegler and PRECIRIX Sign Agreement on Priority Supply...

07/20/2022

Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates...

07/06/2022

Eckert & Ziegler Lowers 2022 Profit Guidance to 27 mm...

07/05/2022

Eckert & Ziegler with Sales Growth in the First Quarter...

05/12/2022

Eckert & Ziegler Cooperates with Czech Research Center UJF to...

05/11/2022

Eckert & Ziegler: Radboud University Medical Center Netherlands to Image...

04/08/2022

Eckert & Ziegler Publishes Preliminary Figures for Q1/2022 with Deviation...

04/06/2022

Eckert & Ziegler with Record Results in FY 2021 and...

03/30/2022

Eckert & Ziegler to Increase Dividend Proposal

03/24/2022

Eckert & Ziegler to Supply Canadian Alpha-9 Theranostics with Lutetium-177...

03/23/2022

Eckert & Ziegler Extends Supply Agreement with Sirtex Medical to...

03/22/2022

Eckert & Ziegler to Supply Telix with Lutetium-177 for Clinical...

02/09/2022

Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176

01/10/2022

Eckert & Ziegler Acquires Argentinian SPECT Specialist

01/03/2022

Eckert & Ziegler Partners with University Health Network and CanProbe...

11/30/2021

Eckert & Ziegler Receives Approval for Gallium-68 Generator for Brasil

11/18/2021

Eckert & Ziegler Announces Clinical Trial Notification for Joint Clinical...

11/12/2021

Eckert & Ziegler: One-Off Effects and Robust Operating Business Push...

11/09/2021

Eckert & Ziegler Acquires Property for Radiopharmaceutical Production Site in...

11/05/2021

Eckert & Ziegler Acquires 53,000 Square Feet Facility for Expansion...

10/11/2021

Nantes University Hospital Doses First Patients with Eckert & Ziegler's...

09/27/2021

Eckert & Ziegler Starts Technetium-99 Delivery in Brazil

08/26/2021

Eckert & Ziegler with Strong First Half of 2021

08/12/2021

Eckert & Ziegler Receives Manufacturing Authorization for Thorium and...

08/09/2021

Eckert & Ziegler Takes over Brazilian Isotope Specialists - Strengthening...

08/02/2021

Half Year Results Stronger than Expected; Eckert & Ziegler Increases...

07/27/2021

Eckert & Ziegler: Affiliates Receives Additional NIAID Funding to Advance...

06/08/2021

Eckert & Ziegler and Telix Pharmaceuticals Enter Co-Promotion Agreement for...

06/03/2021

Eckert & Ziegler Granted Exclusive Distribution Rights by Telix Pharmaceuticals...

05/18/2021

Eckert & Ziegler: Record Income Due to Sale of Division...

05/17/2021

Eckert & Ziegler Signs Long-Term Supply Agreement with Sirtex Medical...

04/28/2021

Eckert & Ziegler Acquires Direct Majority Stake in Drug Developer...

04/16/2021

Eckert & Ziegler to Build cGMP Facility for Radiopharmaceutical Services...

04/14/2021

Eckert & Ziegler Receives Technetium Generator Licenses for Brazil

04/12/2021

Eckert & Ziegler: Dividend Proposal EUR 0.45 per Share. Profit...

03/25/2021

Eckert & Ziegler Divests From Tumour Irradiation Business

03/24/2021

Eckert & Ziegler 2020: Earnings higher than expected

03/17/2021

Eckert & Ziegler to Start Development of Radioisotope Production Facility...

02/12/2021

Eckert & Ziegler Wins Order for Hot Cell Construction from...

02/08/2021

Eckert & Ziegler: PENTIXAPHARM Lead Candidate PENTIXAFOR Can Go in...

02/04/2021

Eckert & Ziegler to Build cGMP Facility for Radiopharmaceutical Services...

01/28/2021

Eckert & Ziegler: Seed Implantation for Prostate Cancer Receives Reimbursement...

01/12/2021

Nine-Month Figures Eckert & Ziegler: Growth in Radiopharmaceuticals Compensates for...

11/10/2020

Eckert & Ziegler to Run Tumor Radiation Business Through TCL...

09/18/2020

Eckert & Ziegler Receives Approval for Gallium-68 Generator for Canada

08/25/2020

Eckert & Ziegler Records Solid Half-Year Results. Growth Trend for...

08/13/2020

Eckert & Ziegler: Implementation of the share split by issuing...

07/30/2020

Eckert & Ziegler Increases Profit Forecast to 4 Euro per...

07/24/2020

Q1 Performance Stable despite Oil Price Slump and Corona Expenses....

05/12/2020

US health authorities to provide USD 6 million in funding...

05/11/2020

Eckert & Ziegler Enters TecDAX

05/06/2020

Eckert & Ziegler with Record Profit in FY 2019

03/31/2020

Eckert & Ziegler: Executive Board Proposes Dividend and Share Split

03/27/2020

Eckert & Ziegler receives CE approval for innovative irradiation applicators...

03/26/2020

Eckert & Ziegler Classified in California as Essential Business

03/22/2020

Eckert & Ziegler Starts Commercial Production of Lutetium-177

03/10/2020

Eckert & Ziegler Reorganizes its Production Sites

03/05/2020

Eckert & Ziegler to Financially Back Clinical Development of Innovative...

03/03/2020

Eckert & Ziegler: Earnings per Share Rise to EUR 4.29...

02/25/2020

Eckert & Ziegler Starts Development Cooperation for Prostate Cancer Diagnosis

02/13/2020

Eckert & Ziegler to Open up US-Production Site for Yttrium-90

02/05/2020

Eckert & Ziegler: Strong nine-month figures. Annual forecast confirmed. Pooling...

11/12/2019

Eckert & Ziegler to supply radioisotopes to Alpha Tau

08/30/2019

Eckert & Ziegler: additional production capacities for Gallium-68-Generators released by...

08/27/2019

Eckert & Ziegler: Strong Growth in Sales and Income

08/13/2019

Eckert & Ziegler forms joint venture for tumor irradiation devices...

08/01/2019

Eckert & Ziegler: EZAG to set up radiopharmaceutical production facility...

07/29/2019

Eckert & Ziegler: EMA Grants Drug Designation to EZAG Affiliate

07/26/2019

Eckert & Ziegler Increases Profit Forecast to 4 Euro per...

07/22/2019

Eckert & Ziegler will be admitted to SDax

06/06/2019

Eckert & Ziegler: Shareholders approve dividend of 1.20 EUR. Frank...

05/29/2019

Eckert & Ziegler will be admitted to the MSCI Germany...

05/14/2019

Eckert & Ziegler off to a strong start in 2019

05/07/2019

Eckert & Ziegler delivers a record result

04/05/2019

Eckert & Ziegler Increases Dividend

03/26/2019

Eckert & Ziegler Awarded for Excellent Training Quality

03/20/2019

Eckert & Ziegler: Merger with Belgian Eckert & Ziegler BEBIG...

02/18/2019

Eckert & Ziegler 2018: Revenue and earnings higher than expected

01/21/2019

Eckert & Ziegler: Extraordinary General Shareholders' Meeting Approves Merger with...

12/20/2018

Eckert & Ziegler Q3/2018: Increase in Revenue in all Business...

11/13/2018

Eckert & Ziegler again Increases Profit Guidance

10/09/2018

Eckert & Ziegler Takes Measures to Significantly Increase U.S. Availability...

10/05/2018

Eckert & Ziegler AG plans intra-group merger with the Belgian...

09/05/2018

Dr. Lutz Helmke appointed as new director at Eckert &...

08/31/2018

Eckert & Ziegler Q2/2018: Increase in Revenue in all Business...

07/31/2018

Eckert & Ziegler increases profit forecast

07/23/2018

Eckert & Ziegler has repurchased 125,000 of its own shares...

07/12/2018

Eckert & Ziegler: Defining the parameters of the public share...

06/21/2018

Eckert & Ziegler is Manufacturing Partner for Bayer's Innovative Targeted...

06/19/2018

Eckert & Ziegler AG: Public Offer to Repurchase Shares

06/01/2018

Eckert & Ziegler has repurchased 125,000 of its own shares...

05/22/2018

Eckert & Ziegler Q1/2018: Sales increase of 9%; earnings remain...

05/08/2018

Eckert & Ziegler: Defining the parameters of the public share...

04/27/2018

Eckert & Ziegler AG: Public Offer to Repurchase Shares

04/16/2018

Eckert & Ziegler Annual Financial Statement 2017: Profit and net...

03/22/2018

Eckert & Ziegler to Recommend Dividend Payment

03/20/2018

Eckert & Ziegler Purchases Manufacturer of X-Ray Devices

12/19/2017

Eckert & Ziegler Q3 / 2017: Continually high income. Net...

11/09/2017

Eckert & Ziegler Q2 / 2017: Income Surges Following Sale...

08/02/2017

Eckert & Ziegler increases profit forecast for financial year 2017

07/25/2017

Eckert & Ziegler: Acquisition of Gamma-Service successfully completed. Albert Rupprecht...

05/31/2017

Eckert & Ziegler Plans Takeover of Gamma-Service

05/24/2017

Eckert & Ziegler invests in capacity expansion for its GalliaPharm(R)...

05/12/2017

Eckert & Ziegler: Sales Growth and Jump in Income in...

05/09/2017

Eckert & Ziegler signs agreement to sell its cyclotron division...

05/05/2017

Eckert & Ziegler 2016 annual financial statements: Sales and profit...

03/23/2017

Eckert & Ziegler to Recommend Dividend Payment

03/21/2017

Eckert & Ziegler: New Executive Board member for Radiation Therapy....

12/23/2016

Eckert & Ziegler Q3/2016: Rise in Radiopharma segment income keeps...

11/03/2016

Eckert & Ziegler: Significant improvement in cost items in the...

08/02/2016

Eckert & Ziegler: Sales Growth and Strong Operating Result in...

05/10/2016

Eckert & Ziegler subscribes to capital increase at BEBIG

04/25/2016

Eckert & Ziegler 2015 Annual Financial Statements: Sales Growth of...

03/23/2016

Eckert & Ziegler: Record Income and Sales in 2015. Strong...

03/21/2016

Eckert & Ziegler expands cooperation program with drug developers in...

02/03/2016

Eckert & Ziegler to sell US seed business

11/30/2015

Eckert & Ziegler: Successful performance in first nine months of...

11/05/2015

Eckert & Ziegler awards prizes to young nuclear medicine researchers

10/13/2015

Record quarter despite restructuring expenses

08/04/2015

Eckert & Ziegler raises profit expectations

06/30/2015

IPSEN to acquire all shares in Octreopharm Sciences GmbH

05/19/2015

Eckert & Ziegler: positive start to the year 2015

05/05/2015

Eckert & Ziegler's SagiNova(R) afterloader receives FDA market clearance

04/23/2015

Eckert & Ziegler's Annual Report 2014: Weak Therapy segment puts...

03/26/2015

Eckert & Ziegler to Recommend Dividend Payment

03/17/2015

Eckert & Ziegler: Disappointing Radiation Therapy business in Eastern Europe...

01/05/2015

Eckert & Ziegler Q3/2014: Sales up, income mixed

11/06/2014

Development candidate SOMscan(R) against neuroendocrine tumors receives orphan drug status...

10/16/2014

Eckert & Ziegler takes over Brazilian isotope specialists - stronger...

09/03/2014

Eckert & Ziegler: Sales growth in first half of year,...

08/05/2014

Eckert & Ziegler: Cancer irradiation systems installed in Ethiopia for...

08/04/2014

Eckert & Ziegler: First patient enrolment for SOMscan(R)

07/01/2014

Eckert & Ziegler gets off to a positive start to...

05/06/2014

Eckert & Ziegler fiscal year 2013: slight decrease in sales....

03/27/2014

Eckert & Ziegler to Recommend Dividend Payment

03/25/2014

Eckert & Ziegler Awards Travel Grants to Young Scientists in...

03/03/2014

Eckert & Ziegler: Drop in Profits for 2013 Expected

01/28/2014

Eckert & Ziegler: Shortfall against 2012 reduced in third quarter,...

11/08/2013

Eckert & Ziegler acquires leading manufacturer of brachytherapy accessories

11/06/2013

Fighting cervical cancer: Eckert & Ziegler wins World Bank tender...

11/04/2013

Eckert & Ziegler acquires American cancer specialist - impact on...

09/17/2013

Eckert & Ziegler Back on Track

08/15/2013

Eckert & Ziegler to join Chinese-German Pharma Development Joint Venture

07/22/2013

Eckert & Ziegler acquires sources and waste business of EnergySolutions...

05/17/2013

Eckert & Ziegler: Modest start to FY 2013

05/03/2013

Eckert & Ziegler Fiscal Year 2012: Sales increased.

03/28/2013

Eckert & Ziegler to Recommend Dividend Payment

03/26/2013

Eckert & Ziegler Abstract Award for Young Scientists Specializing in...

03/08/2013

Eckert & Ziegler Q3/2012: Sales and Earnings in line. Increases...

11/06/2012

Eckert & Ziegler: Solid revenues and earnings in the first...

08/14/2012

Eckert & Ziegler: Positive start to the 2012 financial year

05/03/2012

Eckert & Ziegler: Overproportional Revenue Growth

03/30/2012

Eckert & Ziegler to Recommend Dividend Payment

03/26/2012

Eckert & Ziegler Strahlen- und Medizintechnik AG: Fritz Oesterle reinforces...

12/14/2011

Eckert & Ziegler: 11% Profit Growth in the 9-Month Period

11/02/2011

Eckert & Ziegler awards grants to young researchers in nuclear...

10/19/2011

Eckert & Ziegler: Steady Growth also for 1st Half of...

08/02/2011

Eckert & Ziegler: Andreas Eckert receives ,Man of Action 2011'...

06/08/2011

Eckert & Ziegler: Court Supports Further Modernization in Braunschweig

05/17/2011

Eckert & Ziegler: A profitable First Quarter in 2011

05/03/2011

Eckert & Ziegler withdraws offer to acquire Theragenics

04/06/2011

Eckert & Ziegler: Record Sales with Good Development of Earnings

03/30/2011

Eckert & Ziegler to Recommend Dividend Payment

03/24/2011

Eckert & Ziegler announces offer to Board to Acquire Theragenics

03/17/2011

Eckert & Ziegler with an All-time High in Turnover. Net...

03/15/2011

Eckert & Ziegler to become the long-term contrast agent supplier...

03/02/2011

Eckert & Ziegler to Recommend Dividend Payment

03/24/2010

Eckert & Ziegler Finalizes Take Over Bid IBt

03/24/2010

Eckert & Ziegler: Sales, Profits and Cash Flow at Record...

02/18/2010

Eckert & Ziegler: Associate Company IBt with Record Results

01/21/2010

Eckert & Ziegler: Re-Enter the U.S Market with Therapeutic Products

12/03/2009

Eckert & Ziegler: Strike price for capital increase at 15.95...

11/13/2009

Eckert & Ziegler achieves best six-month result and raises profit...

07/20/2009

Belgian Securities Regulator Asks for Take-over Bid but Suspends Action

04/28/2009

Eckert & Ziegler to Recommend Dividend Payment

03/26/2009

Eckert & Ziegler: Executive Board decides on balance sheet provision...

03/18/2009

Eckert & Ziegler: Court Action taken by a shareholder of...

02/16/2009

Eckert & Ziegler acquires nuclitec

01/23/2009

Eckert & Ziegler: Strike price for capital increase at 5...

01/14/2009

Eckert & Ziegler resolves capital increase

01/12/2009

Eckert & Ziegler to Purchase Isotope Company

12/22/2008

Eckert & Ziegler with special income of EUR 7.3 million

05/05/2008

Eckert & Ziegler and IBt to consolidate Implant Businesses

02/28/2008

Eckert & Ziegler and IBt to consolidate their activities in...

02/18/2008

Eckert & Ziegler: Additional burden of approx. 0.25 EUR per...

07/17/2007

Eckert & Ziegler to Recommend Dividend Payment

03/26/2007

Eckert & Ziegler AG: 20% Growth in Revenues, 37% in...

03/06/2007

Eckert & Ziegler Stops Clinical Development of SpondylAT®

12/20/2006

Eckert & Ziegler: Strong Underlying Growth in 2005

03/29/2006

Eckert & Ziegler AG: 20% Revenue Growth, Earnings Affected by...

01/19/2006

Eckert & Ziegler AG Purchases Rights to a Radiopharmaceutical Rheumatism...

09/15/2005

Eckert & Ziegler to acquire Analytics Inc.

08/11/2005

Eckert & Ziegler AG to Acquire f-con Europe GmbH

06/30/2005

Eckert & Ziegler to Recommend Dividend Payment

03/16/2005

Eckert & Ziegler Strengthens Core Business

06/16/2004

Eckert & Ziegler to Acquire Radiation Product Business of HEK...

03/16/2004

Eckert & Ziegler to Acquire CIS bio Afterloader Business

11/21/2003

NEMOD Demonstrates Promising Preclinical Anti-Cancer Results for PankoMab(TM)

10/20/2003

Eckert & Ziegler: Reimbursment of Seed Implantation

10/16/2003

Eckert & Ziegler: Development in the First Quarter of 2003...

05/13/2003

Eckert & Ziegler: Positive Result Despite High Expenditure for Product...

03/27/2003

Eckert & Ziegler to Exercise it's Option for Stock Buy...

02/19/2003

Eckert & Ziegler Expects a Balanced Result for 2002 and...

02/12/2003

Eckert & Ziegler AG: Sale of Production Line and U.S....

02/06/2003

Eckert & Ziegler: Strong Profit Growth in the Third Quarter

11/12/2002

Eckert & Ziegler AG: Uphill Struggle against the Dollar Exchange...

08/13/2002

Eckert & Ziegler: Double-Digit Growth in First Quarter

05/28/2002

Eckert & Ziegler granted FDA clearance for prostate seeds

05/21/2002

Eckert & Ziegler to Market Prostate Cancer Products in the...

05/15/2002

Successful First Quarter for Eckert & Ziegler

05/06/2002

Eckert & Ziegler: Stock Buy Back Programm Approved

04/23/2002

Eckert & Ziegler: Profit for the year 2001 rises by...

03/27/2002

Eckert & Ziegler: annual turnover for 2001 up by nearly...

01/24/2002

Eckert & Ziegler steps up biotechnology business

12/13/2001

Eckert & Ziegler: Solid organic growth - EUR 0.95 net...

11/13/2001

Eckert & Ziegler to take one-time charge for cardio-vascular area

10/01/2001

Eckert & Ziegler Sells Off The Non-Strategic Segment of Its...

09/27/2001

Record Levels for Half Year Sales and Earnings

08/14/2001

Eckert & Ziegler to Develop Radiolabelled Antibodies

07/27/2001

Eckert & Ziegler Receives Global Supply Contract from General Electric...

07/03/2001

Large Order For Medical Radiation Sources

06/19/2001

Eckert & Ziegler: Solid Growth Continues

05/29/2001

Eckert & Ziegler Ends Legal Dispute Surrounding Major Project Receives...

05/11/2001

Eckert & Ziegler AG Appoints New Board Member Solid Sales...

05/04/2001

Eckert & Ziegler with Record Results in Sales and Profits...

03/28/2001

Eckert & Ziegler Cooperates with an Outpatient Brachytherapy Center

02/27/2001

Eckert & Ziegler Exceeds its Revenue Expectations

01/10/2001

Press Releases

Eckert & Ziegler Achieves Further Earnings Growth and Double-Digit Sales...

Eckert & Ziegler Gains Approval for GalliaPharm® in Japan

Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation...

Eckert & Ziegler: Further Increase in Earnings in the First...

Eckert & Ziegler: Implementation of the Share Split by Issuing...

Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation...

Eckert & Ziegler: Capital Increase Entered in the Commercial Register....

Eckert & Ziegler: Outstanding Training Quality Once Again Awarded

Annual General Meeting of Eckert & Ziegler SE Approves Dividend...

Eckert & Ziegler: Illuccix® PSMA-PET Imaging Agent Receives Approval in...

Eckert & Ziegler Organizes Third Boston Radionuclide Theranostics Forum

Eckert & Ziegler Wins “Best Managed Companies Award” for the...

Eckert & Ziegler Starts with Earnings Growth in Q1 2025...

Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher...

Eckert & Ziegler Proposes Dividend of € 0.50 for...

Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig

Eckert & Ziegler: Record year 2024 with new all-time highs

Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for...

Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global...

Eckert & Ziegler Enters Strategic Partnership with Bicycle Therapeutics for...

Eckert & Ziegler Ensures Business Continuity After Cyber-Attack

Eckert & Ziegler Affected by Cyber Attack

Eckert & Ziegler SE: IT Incident Affects Eckert & Ziegler...

Eckert & Ziegler Announces Preliminary Figures for 2024: Significant Increase...

Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese...

Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply...

Eckert & Ziegler Submits GalliaPharm® for Approval by Japan’s Health...

Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement...

Eckert & Ziegler: Changes in the Executive Board and Supervisory...

Eckert & Ziegler Begins Production of Actinium-225, Paving the Way...

Eckert & Ziegler Achieves European Approval for Theralugand® - Lutetium-177...

Eckert & Ziegler raises its forecast for the current financial...

Eckert & Ziegler Continues on Growth Path with Strong 9-Month...

Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration...

Eckert & Ziegler Again Increases Sales and Earnings in the...

Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply...

Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the...

Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering...

Eckert & Ziegler becomes European contract manufacturer for Telix's innovative...

Eckert & Ziegler Continues Sales and Earnings Growth in the...

Eckert & Ziegler extends GalliaPharm® availability to the entire European...

Eckert & Ziegler Again Increases Sales and Earnings Compared to...

Annual General Meeting of Eckert & Ziegler SE Approves Split-Off...

Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to...

Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility

Eckert & Ziegler Hosts Second Radionuclide Theranostics Forum in Boston,...

Eckert & Ziegler receives “Best Managed Companies Award”

Eckert & Ziegler with significant increase in sales (+17%) and...

Eckert & Ziegler: Q1 with Significant Increase in Sales and...

Eckert & Ziegler Continues on Growth Path after Successful Financial...

Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving...

Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings...

Eckert & Ziegler Completes Change of Legal Form to SE

Eckert & Ziegler Extends Ga-68 Activities in Japan

Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes...

Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement...

Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership...

First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study...

Eckert & Ziegler: Personnel Changes in the Management. Changes in...

Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma...

Eckert & Ziegler with Significant Sales Growth in the First...

Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for...

Eckert & Ziegler and Supervisory Board Decide on Investment Priorities...

Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off...

Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous...

Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply...

Eckert & Ziegler Receives Award for Professional Training

Eckert & Ziegler Signs Strategically Important Agreement for the Supply...

Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals...

Eckert & Ziegler Continues Positive Sales Development in the First...

Eckert & Ziegler again achieves sales growth compared to the...

Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to...

ckert & Ziegler: Annual General Meeting Approves Dividend of EUR...

Eckert & Ziegler to Host First Radionuclide Theranostics Forum in...

​​​​​​​Reorganization in the Executive Board of Eckert & Ziegler

Eckert & Ziegler with Strong Sales Growth in the First...

Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins...

Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit...

Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177

Reorganization in the Executive Board of Eckert & Ziegler

Eckert & Ziegler: Successful fiscal year 2022

Eckert & Ziegler Plans Change of Legal Form to European...

Eckert & Ziegler: Nine-Month Figures Show Strong Sales Growth

Eckert & Ziegler with Successful First Half of 2022

Eckert & Ziegler Publishes Preliminary Figures for Q1/2022 with Deviation...

Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176

Eckert & Ziegler Acquires Argentinian SPECT Specialist

Eckert & Ziegler with Strong First Half of 2021

Half Year Results Stronger than Expected; Eckert & Ziegler Increases...

Eckert & Ziegler: Record Income Due to Sale of Division...

Eckert & Ziegler Acquires Direct Majority Stake in Drug Developer...

Eckert & Ziegler to Build cGMP Facility for Radiopharmaceutical Services...

Eckert & Ziegler: Dividend Proposal EUR 0.45 per Share. Profit...

Eckert & Ziegler Divests From Tumour Irradiation Business

Eckert & Ziegler to Build cGMP Facility for Radiopharmaceutical Services...